A pan‐European collaboration cryed the ETERNAL project is set tae transform pharmaceutical manufacturin by reducin its environmental fitprint throu sustainable chemical an physical processes. The initiative, that brings thegither saxteen pairtners fae industry, academia, an research institutes, emphasises fu life cycle approaches—fae drug design an manufacture tae product disposal—for tae minimise pollution, resoorce depletion, an greenhoose gas emissions.
The pharmaceutical industry faces growin scrutiny ower its contribution tae environmental degradation throu complex chemical syntheses, resoorce-intensive production, an waste generation. ETERNAL sikks tae address thae challenges by incorporatin green chemistry principles, mechanochemistry, an digitalisation tae optimise process performance an safety. The project’s framewark focuses on reducin solvent yaise, enhancin resoorce recovery, an acceleratin process optimisation while ensurin compliance wi evolvin environmental regulations.
Quotient Sciences, a key pairtner in the consortium, is leveragin its expertise in digitalisation as pairt o the ETERNAL project. Their wark includes developin Digital Twins tae simulate an optimise processes. Thae digital representations aim tae reduce laboratory experimentation by allouin virtual experiments that consume fewer reagents an solvents. As stated in the project documents, Quotient Sciences “aims tae reduce the nummer o experiments required at the laboratory or pilot scale, thereby minimisin resoorce consumption an waste generation.” Their approach no ainly streamlines the scale-up o active pharmaceutical ingredient synthesis but provides real-time monitorin, reducin the risk o deviations an waste.
The Digital Twin technology developed by Quotient Sciences is a central component o the project’s strategy tae improve process efficiency an environmental performance. By enablin a reduction in physical experiments, the technology supports a mair sustainable approach tae drug development an manufacturing. This innovation is reflective o the braider industry move tae integrated solutions that prioritise baith environmental an economic benefits. The decreasin need for extensive lab-scale experimentation has the potential tae significantly cut emissions an reduce the yaise o hazardous chemicals.
The ETERNAL project addresses hazardous waste management, the environmental risks associated wi active pharmaceutical ingredients, an the adoption o a circular economy model in manufacturing. The initiative encourages the yaise o renewable feedstocks, energy-efficient processes, an real-time analysis an monitorin for tae foster safer, mair efficient operations.
As regulatory demands increase an societal expectations for environmental responsibility intensify, the collaborative efforts ithin ETERNAL unnerline an industry-wide commitment tae achieve sustainable pharmaceutical manufacturing. The project’s integrated approach micht serve as a blaeprint for ither global companies sikkin tae reduce their environmental impact while maintainin heich product quality an operational efficiency.